Eagle Asset Management Inc Kodiak Sciences Inc. Transaction History

Eagle Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$7.09 - $89.45 $1.29 Million - $16.3 Million	-182,540 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$80.85 - $128.49 $2.1 Million - $3.34 Million	-25,992 Reduced 12.46%	182,540 $16.2 Million
Q3 2021 Nov 10, 2021	SELL	$81.97 - $106.94 $3.26 Million - $4.25 Million	-39,771 Reduced 16.02%	208,532 $20 Million
Q2 2021 Aug 11, 2021	BUY	$77.2 - $126.54 $463,508 - $759,746	6,004 Added 2.48%	248,303 $23.1 Million
Q1 2021 May 14, 2021	BUY	$110.45 - $164.47 $1.65 Million - $2.46 Million	14,982 Added 6.59%	242,299 $26.4 Million
Q4 2020 Feb 12, 2021	BUY	$60.78 - $154.03 $13.8 Million - $35 Million	227,317 New	227,317 $33.4 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $450M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.